BEER-SHEVA, Israel, Feb. 9, 2021 /PRNewswire/ -- Researchers at Ben-Gurion Universityof the Negev (BGU) have developed a new method for rapidly diagnosing brain blood vessel pathology that may lead to neurodegenerative diseases, such as Alzheimer's disease, as well as other neurological and psychiatric conditions, including epilepsy, traumatic brain injury and stroke. The novel method is based on analysis of EEG patterns using proprietary algorithms and was invented by Dr. Dan Milikovsky and Prof. Alon Friedman, MD-PhD, Departments of Physiology and Cell Biology, Cognitive and Brain Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev.

The novel diagnostic method is based on findings from the lab of Prof. Friedman that patients with Alzheimer's disease and other brain conditions display nonconvulsive epileptic seizure-like activity that can be detected by EEG recordings. The study was published in the highly ranked Science Translational Medicine Journal [i]. This abnormal activity reflects pathological changes in dysfunction of the brain blood vessels, which contribute, according to recent studies, to the pathogenesis of various neurodegenerative and other neuro-psychiatric disorders.

"Research from our lab and others, shows that the pathological changes in the brain blood vessels, which are usually referred to as the blood-brain barrier (BBB), contribute to the formation of Alzheimer's disease and other brain disorders. Since dysfunction of the BBB is also a key component in the pathogenesis of epilepsy, we hypothesized that BBB dysfunction in Alzheimer's patients would also trigger abnormal brain activity that could be detected by EEG, an accessible and affordable tool used in the clinic, and serve as a diagnostic method for these conditions," explained Prof. Friedman. "Indeed, we find abnormal, epileptic-like EEG recordings in many patients with Alzheimer's disease as well as epilepsy, which reflect brain blood vessel pathology and can serve both for diagnosis as well as a therapeutic target."

The technology was successfully tested on animal models and dozens of patients and is now been validated on large databases of EEG records of thousands of patients.

"This new approach for diagnosing neurological conditions based on analysis of changes of blood vessels in the brain can be valuable for the early detection of Alzheimer's disease and other neurological conditions, at the stage when treatment can still slow down disease progression. The technology offers a biomarker for immediate results and allows for the continuous monitoring of the progression of the neurological condition and response to treatment," said Josh Peleg, CEO of BGN Technologies. "We are now seeking a potential industry partner for the further development of this promising method for a variety of applications, from monitoring of ICU patients, to patients after stroke and head injuries and for the diagnosis of vascular pathology in early Alzheimer's disease."

About BGN Technologies

BGN Technologiesis the technology transfer companyof Ben-Gurion University, the third largest university in Israel. BGN Technologies brings technological innovations from the lab to the market and fosters research collaborations and entrepreneurship among researchersand students. To date, BGNTechnologieshas established over 100 startup companiesin the fields of biotech, hi-tech, and cleantech, and has initiated leading technology hubs,incubators, and accelerators.Over the past decade, BGN Technologies has focused on creating long-term partnerships with multinational corporations such as Deutsche Telekom, Dell-EMC, PayPal, and Lockheed Martin, securing value and growth for Ben-Gurion University as well as the Negev region.For more information, visit the BGN Technologies website.

[i] Milikovsky1 et al. (Dec. 2019), Paroxysmal slow cortical activity in Alzheimer's disease and epilepsy is associated with blood-brain barrier dysfunction. Science Translational Medicine: Vol. 11, Issue 521, eaaw8954.

Media Contact:Tsipi HaitovskyGlobal Media LiaisonBGN TechnologiesTel: +972-52-598-9892E-mail: [emailprotected]

SOURCE BGN Technologies

See more here:
Ben-Gurion University Researchers Introduce New Method for Diagnosing Neurological and Psychiatric Conditions - PRNewswire

Neurological Biomarkers Market Report recently published by Worldwide Market Reports company focuses mostly on required solutions to the users. The study includes analysis, forecast, and revenue from 2021 to 2026. The advancement rate is evaluated dependent on insightful examination that gives credible information on the worldwide market. Imperatives and advancement points are merged together after a significant comprehension of the improvement of this market.

There is Continuous growth in the Neurological Biomarkers Market in the last five years and also continued for the forecasted period. Neurological Biomarkers industry report analyses the outline of the global market with respect to major regions and segmented by types and applications. This report covers top manufacturers, product scope, market overview, market opportunities, market risk, market driving force, technological advancement, distributors, traders, dealers, research findings.

RequestMore Detailed Information About Industry: Get Sample Report Click Here!

The top players covered in Neurological Biomarkers Market are: Abbott, QIAGEN, Thermo Fisher Scientific, Athena Diagnostics, Bio-Rad Laboratories

The point-to-point elucidation of the markets assembling system, the usage of advancement, conclusions of the world market players, dealers and suppliers order, and the explicit business data and their improvement plans would help our customers for future courses of action and movement planned to make due in the Neurological Biomarkers market.

The data always remains relevant to the market and consists of market dynamics, prospects, starts, market dynamics, and even the Global market volumes into account. It filled with data and deep analysis on market value, environmental analysis, Neurological Biomarkers advanced techniques, latest developments, Neurological Biomarkers business strategies, and current trends. Hence, it becomes a valuable asset to both manufacturers and investors of the industry.

Points Covered of this Neurological Biomarkers Market report are:

The international Neurological Biomarkers market has been characterized by several primary factors, with each factor tends to play a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially.

The analysis and forecast of the global market of Neurological Biomarkers have no longer been, specifically, analyzed that are not only on a global foundation but additionally on a neighborhood foundation. When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Request Discount for this Research:(Click Here!)

Research Methodology:

The Neurological Biomarkers market report has been prepared after thorough market research being conducted. It has been prepared as per Porters Five Force Model. In terms of timeline, the market takes the period between 2021-2026 into account for assessment. Apart from this, a comprehensive SWOT analysis has been provided for swift business decision making.

Enumerating some of the fundamental parameters encompassed in the report:

Global Neurological Biomarkers Market Report includes Detailed TOC points:

Customization Service of the Report: (Place Query: Click Here!)

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

Contact Us:Mr. ShahWorldwide Market Reports,Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737Email: sales@worldwidemarketreports.com

See the original post:
Covid-19 Impact on Neurological Biomarkers Market Size, Share, Trends and Forecast 2021-2026: Abbott, QIAGEN, Thermo Fisher Scientific - KSU | The...

Genetically determined smoking behavior is associated with an increased risk for non-traumatic subarachnoid hemorrhage (SAH), according to study results published in Stroke.

Data suggest that smoking is an important risk factor for aneurysm formation and rupture. While previous studies have identified an increased risk for non-traumatic SAH among smokers, the causal association is not well understood. The objective of this study was to determine if smoking is causally related to the risk for SAH.

Study researchers conducted this large prospective study with Mendelian Randomization analyses using data from the UK BioBank, a large cohort study with over 500,000 adults (age, 40-69 years) from 2006 to 2010. Of the 408,609 patients evaluated, 132,566 (32%) ever smoked regularly and 902 (0.22%) were diagnosed with SAH.

A polygenic risk score that represents the genetic propensity to smoke was built using individual-level genetic data and included 126 single nucleotide polymorphisms.

There was a strong association between genetic susceptibility to smoking with both smoking initiation and risk of SAH. Each additional SD of the smoking polygenic risk score was associated with a 21 percent increased risk for smoking initiation (odds ratio [OR], 1.21; 95% CI, 1.20-1.21; P <.001) and with a 10 percent increased risk for SAH (OR, 1.10; 95% CI, 1.03-1.17; P =.006).

In the primary Mendelian Randomization analysis using the ratio method, genetic susceptibility to smoking was linked to a 63 percent increase in risk of SAH (OR, 1.63; 95% CI, 1.15-2.31; P =.006). The results were similar on secondary Mendelian Randomization analyses using the inverse variance weighted method (OR, 1.57; 95% CI, 1.13-2.17; P =.007) and the weighted median method (OR, 1.74; 95% CI, 1.06-2.86; P =.03).

Findings indicated that the genetic susceptibility to smoking initiation was associated with a 60 percent increase in the risk of SAH, and, compared with never smokers, this increased risk was similar for those who smoked 0.05 to 20 packs per year (OR, 1.63; 95% CI, 1.01-2.62; P =.04), 20 to 40 packs per year (OR, 1.65; 95% CI, 1.13-2.41; P =.009) and more than 40 packs per year (OR, 1.56; 95% CI, 1.08-2.25; P =.02).

The study had several limitations, according to the study researchers, including potential misclassification of the outcome secondary to use of ICD codes to determine SAH cases, the absence of an independent dataset to confirm the results, and the limited demographic of the study population (all genetically determined White study participants). As a result, findings cannot be applied to other racial and/or ethnic populations.

We found that a stronger genetic predisposition to smoking is significantly associated with an increased risk of SAH. These findings provide important evidence to support a causal relationship between smoking and the risk of SAH, concluded the study researchers.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Acosta JN, Szejko N, Both CP, et al. Genetically determined smoking behavior and risk of nontraumatic subarachnoid hemorrhage. Stroke. Published online January 14, 2021. doi:10.1161/STROKEAHA.120.031622

More here:
The Association Between Smoking and Subarachnoid Hemorrhage - Neurology Advisor

Long-term disease modifying therapies for patients with multiple sclerosis (MS) were effective at reducing relapse and disability accumulation, according to study results published in Neurology.

The predominant goal of MS treatments is the prevention of long-term disability accrual. Study researchers sought to determine whether immunotherapy could prevent long-term disability in patients with relapsing-remitting MS.

In this observational cohort study, researchers assessed patients (N=14,717) with MS who were eligible for class IV immunotherapy. They collected patient data from the MSBase registry.

71% of patients were women (mean age, 36 years; mean age at disease onset, 309 years) and had a median of 6 (interquartile range [IQR], 3.1-10) years of prospective follow-up data. Patients had a median of 4 (IQR, 2-6) relapses, and 69% were exposed to immunotherapies. A total of 1085 patients had at least 15 years of follow-up data (median years of prospective follow-up, 17 years; 95% CI, 15.6-18.8).

Patients who received continuous treatment were less likely to have a relapse event compared with those who were not continuously treated (annual relapse rate, 0.32 vs 0.46, respectively; hazard ratio [HR], 0.60; 95% CI, 0.43-0.82; P =.0016) and less likely to have a 12-month confirmed disability accumulation event (disability accumulation, 0.9 vs 1.5 events, respectively, at 15 years; HR, 0.56; 95% CI, 0.38-0.82; P =.0026).

Compared to untreated patients, fewer patients with continuous treatment reached an Expanded Disability Status Scale (EDSS) step 6 at 15 years (41% vs 13%, respectively; HR, 0.33; 95% CI, 0.19-0.59; P =.00019).

Study researchers did not observe significant difference in disability improvement between the treated and untreated patients (HR, 1.20; 95% CI, 0.96-1.50; P =.1). They also observed similar patterns, stratified by disease duration and age, between these two cohorts.

Limitations of this study include its observational design, the inability to assess delayed treatment effects, and the inability to generalize findings beyond patients with MS followed in academic centers.

These data indicated patients receiving long-term immunotherapy were at decreased risk for disease relapse and neurologic disability escalation. The study authors concluded that sustained, long-term immunotherapy from early stages of MS is advisable as a strategy to preserve patients neurological capacity over the long-term.

Disclosure: Multiple authors declared affiliations with the pharmaceutical industry. Please refer to the original article for a full list of disclosures.

Reference

Kalincik T, Diouf I, Sharmin S, et al. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. Published online December 28, 2020. doi:10.1212/WNL.0000000000011242

The rest is here:
Long-Term Immunotherapy Linked to Reduced Relapse in Relapsing-Remitting MS - Neurology Advisor

London, Dec. 01, 2020 (GLOBE NEWSWIRE) -- In its latest publication, titled Research Antibodies and Reagents Market by Product {Antibodies [Type (Primary, Secondary), Production, Source, Research Area (Oncology, Neurology)], Reagents}, Technology (ELISA, Western Blot), Application, End User (Pharma, Academia) - Global Forecast to 2027, Meticulous Research analyses that the research antibodies and reagents market is expected to grow at a CAGR of 5.6% from 2020 to reach $6.32 billion by 2027.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Traditionally, antibodies were obtained from blood and serum. However, these antibodies were produced in a limited number and may cause cross-reactivity. This led to an increase in their cost, along with decreasing use in basic research. To overcome these drawbacks and decrease the outgrowth of various diseases, researchers developed different types of antibodies using sophisticated technologies that can produce a large number of antibodies within less time with high specificity and affinity than traditional ones. Thus, to promote research activities, advanced technologies using research antibodies and reagents products are widely used by various end-users.

Factors such as the increasing proteomics and genomics research studies, increased funding for research activities, and growing industry-academia collaborations are majorly driving the research antibodies and reagents market. Also, growing economies, rising protein-based research, and increasing biomarker discovery provide opportunities for the growth of the market. In addition, the growing growing number of research activities due to increasing COVID-19 cases all over the globe is further driving the adoption of research antibodies and reagents by various end-users.

To provide efficient analysis, Meticulous Research has segmented this market by product {antibodies [type (primary antibody, secondary antibody), production type (monoclonal antibody, polyclonal antibody, and antibody fragments), source (mouse, rabbit, and others), research area (oncology, cardiovascular disease, infectious diseases, immunology, neurology, stem cell research, and others)], reagents [sample preparation reagents (media and serum, stain and dyes, probes, buffers, and solvents), antibody production reagents (enzymes and proteins), other research reagents}, technology (western blot, immunofluorescence, ELISA, multiplex immunosorbent assay, flow cytometry, immunohistochemistry, immunoprecipitation, and others), application (proteomics, drug discovery and development, and genomics), end user (pharmaceutical and biotechnology industry, academic and research institutes, and contract research organizations), and geography (Asia-Pacific, Europe, North America, the Middle East & Africa, and Latin America).

Wish to customize this report or get any additional specific information of your interest? Let us know here-https://www.meticulousresearch.com/custom-research.php

In 2020, geographically, North America is projected to command the largest share of the research antibodies and reagents market, closely followed by Europe and Asia-Pacific. However, Asia-Pacific region is expected to grow at the fastest rate due to growing R&D investment in proteomics research, rising middle-income people, growing focus on the pharma sector, and improving healthcare industry.

Based on product, the reagents segment is projected to grow at the fastest growth rate of the overall research antibodies and reagents market due to increasing focus on understanding the molecular basis of diseases and routine use in target-based assays during the basic research and huge demand for various reagents in many routine assays.

In 2020, the flow cytometry segment is expected to command the largest share of the overall research antibodies and reagents market. Growing focus on biomedical research for improving diagnosis and therapy developments and growing focus on biomarker discovery and cell-based research are the key factors driving the growth of this segment.

In 2020, on the basis of application, the proteomics segment is poised to command the largest share of the overall research antibodies and reagents market. The upsurge in proteomics research is attributed to the rising need to design more effective drugs through protein-based disease profiling, rising uptake of research antibodies in the significantly growing proteomics market, and increasing public & private sector spending on proteomic research.

Quick Buy -Research Antibodies And Reagents Market Research Report:https://www.meticulousresearch.com/buy_now.php?pformat=356&vformat=1055

On the basis of end user, in 2020, the pharmaceutical and biotechnology industry segment is estimated to command the largest share of the research antibodies and reagents market due to the highest adoption of antibodies and reagents by this end-user for increasing research activities.

The report includes a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the past four years (2016-2019). The key players profiled in the research antibodies and reagents market are GE Healthcare (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann La-Roche AG (Switzerland), Rockland Immunochemicals Inc. (U.S.), Johnson & Johnson (U.S.), Agilent Technologies, Inc. (U.S.), Eli Lily and Company (U.S.), Becton Dickinson and Company (U.S.), Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), GenScript Biotech Corporation (U.S.), Lonza (Switzerland), Bio-Techne Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Santa Cruz Biotechnology, Inc. (U.S.), and BioLegend, Inc. (U.S.) among others.

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Scope of the Report:

Research Antibodies And Reagents Market, by Product Type

Research Antibodies And Reagents Market, by Technology

Research Antibodies And Reagents Market, by Application

Research Antibodies And Reagents Market, by End User

Research Antibodies And Reagents Market, by Geography

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5055

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports:

Contract Research Organizations (CRO) Market by Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027

https://www.meticulousresearch.com/product/CRO-market-5129/

In Vitro Diagnostic (IVD) Reagents Market by Type (Antibodies, Oligonucleotide, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) Global Forecast to 2027

https://www.meticulousresearch.com/product/in-vitro-diagnostic-reagents-market-5110/

Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

https://www.meticulousresearch.com/product/infectious-disease-diagnostics-market-4976/

COVID-19 Diagnostics (PCR Testing, Antibody Testing) and Therapy (Immunotherapy, Vaccines, Antiviral, Cell-based, Plasma therapy) Market Opportunity Assessment and Global Forecast to 2025

https://www.meticulousresearch.com/product/COVID-19-impact-assessment-health-and-life-sciences-industry-5098/

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr. Khushal BombeMeticulous ResearchDirect Lines: +1-646-781-8004 (North America)+44-203-868-8738 (Europe)+91 744-7780008 (Asia-Pacific)Email-sales@meticulousresearch.comVisit Our Website:https://www.meticulousresearch.com/Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-researchContent Source:https://www.meticulousresearch.com/press-release/research-antibodies-reagents-market-2027/514

Excerpt from:
Research Antibodies and Reagents Market to Reach $6.32 Billion by 2027 With COVID-19 Impact, at a CAGR of 5.6% from 2020- Meticulous Research Analysis...

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the 31st International Symposium on ALS/MND taking place online from December 9 December 11, 2020.

Title: A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS): COURAGE-ALS Trial DesignSession: Live Poster Session ADate: December 9, 2020Theme: 09 Clinical Trials and Trial DesignPresentation Time: 5:10 5:50 PM GMTPoster Number: CLT-04Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology atBarrow Neurological Institute, and Professor and Executive Chair of Neurology at theUniversity of Arizona,Phoenix

Title: Impact of Patient Characteristics on Effect Size in FORTITUDE-ALSSession: Live Poster Session BDate: December 10, 2020Theme: 09 Clinical Trials and Trial DesignPresentation Time: 5:10 5:50 PM GMTPoster Number: CLT-17Poster Presenter: Jeremy M. Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology atBarrow Neurological Institute, and Professor and Executive Chair of Neurology at theUniversity of Arizona,Phoenix

Title: People Living with ALS and Their Caregivers Input into Drug Development in EuropeSession: Live Poster Session CTheme: 13 Clinical Management, Support and InformationDate: December 11, 2020Presentation Time: 12:05 12:50 PM GMTPoster Number: CMS-33Poster Presenter: Miriam Galvin, Ph.D., Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3 pending ongoing regulatory interactions. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information aboutCytokinetics, visitwww.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential benefits of reldesemtiv, including its ability to represent an additive and complementary approach to increase muscle function; Cytokinetics and its partners research and development activities; the timing of enrollment of patients in Cytokinetics and its partners clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics or its partners ability to conduct clinical trials; and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas decisions with respect to the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; standards of care may change, rendering Cytokinetics drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Communications, Investor Relations(415) 290-7757

Read more:
Cytokinetics Announces Three Presentations at the International Symposium on ALS/MND - GlobeNewswire

Long-term follow-up from the phase 3 ORATORIO extension study (ClinicalTrials.gov Identifier: NCT01194570) provided evidence of a consistent, long-term benefit of early and continuous ocrelizumab treatment on disease progression in primary progressive multiple sclerosis (PPMS), according to study results published in the Lancet Neurology.

Data from the phase 3 ORATORIO trial supported the safety and efficacy of ocrelizumab for patients with PPMS. The objective of this follow-up study was to evaluate the long-term safety and efficacy of maintaining or switching to ocrelizumab therapy in the open-label extension phase of the trial.

ORATORIO was a multi-center, double-blind, phase 3 trial of 732 patients with PPMS. Patients were aged 18-55 years and randomly assigned to receive intravenous ocrelizumab or placebo, every 24 weeks for at least 120 weeks. After the double-blind phase, the participants entered an extended controlled period, followed by an open-label extension phase, during which they continued ocrelizumab or switched from placebo to ocrelizumab.

Time to onset of disability progression was confirmed at 24 weeks months by using 4 measures: increase in Expanded Disability Status Scale score; 20% or more increase in time to complete the 9-Hole Peg Test; 20% or more increase in time to perform the Timed 25-Foot Walk; and composite progression, defined as the first confirmed occurrence of any of these three individual measures.

Of 732 participants, 544 (74%) completed the double-blind period to week 144; 517 of these patients and 10 additional ones (total, 527 [72%]) entered the open-label extension phase. Of the 527 patients, 451 (86%), were ongoing in the open-label extension.

Over a period of 6.5 study years, there was a consistent and sustained treatment-associated benefit in multiple measures of disability progression. The proportion of patients with worsening disability measures was lower in those who initiated ocrelizumab early, compared with those who switched from receiving placebo: Expanded Disability Status Scale (51.7% vs 64.8%, respectively; P =.0018); 9-Hole Peg Test (30.6% vs 43.1%, respectively; P =.0035); Timed 25-Foot Walk (63.2% vs 70.7%, respectively; P =.058), and composite progression (73.2% vs 83.3%, respectively; P =.0023).

Percent changes in T2 lesion volume (0.447% vs 13.002%, respectively; P <.0001) and T1 hypointense lesion volume (36.676% vs 60.925%, respectively; P =.0008) from baseline to the end of the study were lower for patients who were on ocrelizumab from the double-blind phase of the study, compared with those who switched from placebo.

The rate of adverse events and serious adverse events over the entire period in the all-ocrelizumab exposure population were 238.09 (95% CI, 232.71-243.57) per 100 patient-years and 12.63 (95% CI, 11.41-13.94) per 100-patient years, respectively. The most common serious adverse events were serious infections with a rate of 4.13 (95% CI, 3.45-4.91) per 100 patient-years. No new safety signals emerged.

The study had several limitations, including the lack of a control group, open-label treatment, and potential survivor bias.

Although this study shows the benefit of earlier intervention with ocrelizumab in primary progressive disease, progression remains an important unmet need in multiple sclerosis, concluded the study researchers.

Reference

Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. Published online October 29, 2020). doi:10.1016/S1474-4422(20)30342-2

Follow this link:
Sustained Benefit of Ocrelizumab Treatment for Primary Progressive MS - Neurology Advisor

InYourArea Community

Between December 1 and December 8, there'll 10,000 of match-funding available for donations to Neuro Therapy Centres

Centre member Clare Moulton using the Neuro Therapy Centres gym

Submitted by The Neuro Therapy Centre, edited by Lucy Hilton

A local charity is calling for community support as they're given a fantastic opportunity.

The team at the Neuro Therapy Centre have recently made their 5,000th support call, as their services support people with neurological conditions across the region.

They're now asking for help to keep their Virtual Centre going as donations supporting their services will be match-funded next month.

Staff at the Centre are urging as many people to get involved as possible at this important time by making a donation to help fund their vital work.

The Centre started offering many of its life-changing services online in April as a result of the pandemic, and as they adapted their delivery, the charity has found new ways to help people across the region with plans to expand their work in the future.

Jane Johnston-Cree, Centre Director at the Neuro Therapy Centre said: "This year has been a challenging one for all of us.

The Centres virtual services now feature regular telephone support, telephone and online counselling sessions, nine live exercises sessions a week and a range of recorded exercise sessions and therapies.

Jane added: "Our virtual services are helping people who sometimes find it a struggle to visit our Centre in Saltney due to transport or work commitments.

Clare Moulton, from Sychdyn in Flintshire, was diagnosed with MS in 1997, and has been attending physiotherapy and gym sessions at the Neuro Therapy Centre since 2018.

The Centre re-opened in September for in-Centre services but it will be next year before the same number of people will be able to attend its services on a weekly basis in person.

Jane said: "We intend to keep our virtual centre going alongside our in-Centre services in the future, which is why wed love as many people as possible to get behind our match-funding Big Give campaign.

"We know transport can be a real issue, and if these services can help people who have been newly diagnosed and are still in work too that would be fantastic."

Between noon on December 1 and noon on December 8, the Neuro Therapy Centres Big Give web page will be live, and there is 10,000 of match-funding available for donations of any size to be doubled for free.

The Centre also has an online Christmas Concert with local artists Matt Violet and The Last Minute performing on Saturday, December 5, and is encouraging people to wear a Christmas jumper and make a donation to the site during that week.

If people would like to make a donation to the Neuro Therapy Centre visit their Big Give page.

The Neuro Therapy Centre, based in Saltney, Chester, supports people with neurological conditions including MS, Parkinsons, ME and MND, and their Carers from across Cheshire, North Wales and the Wirral.

If people would like to find out more about the services of the Neuro Therapy Centre or to book a ticket for the Christmas Concert visit their website.

Shine a spotlight on your neighbourhood by becoming an Area Ambassador.

Click here to learn more!

Continued here:
Neurological charity's donations to be doubled with match-funding next month - In Your Area

Global Brain Monitoring Devices Market: Overview

The National Institute of Mental Health in the US states that every 1 in 4 adults suffers from a brain disorder every year. It further asserts that at least 6% suffer from serious disabilities due to severe brain damage. This alarming statistic goes to show the dire need for brain monitoring devices in the global healthcare industry today. Research shows that brain monitoring devices will be in significant demand in critical care units due to a high incidence of accidents pertaining to brain trauma and injuries in recent past. The market offers a wide range of devices to treat the abnormal brain activities and restore its functioning, depending on the case.

The global brain monitoring market has been analyzed by researchers at Transparency Market Research using foolproof research methodologies. The document has been collaborated using information from various journals, interviews, whitepapers, conferences, and magazines. The report also includes an assessment of the competitive landscape present in the global brain monitoring devices market. It offers a thorough understanding of the overall market dynamics and maps a plausible trajectory for the market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1322

Global Brain Monitoring Devices Market: Drivers and Trends

The high incidence of neurological disorders in recent years due to changing lifestyles, rising stress levels, and radical changes in the social environments have cumulatively augmented the demand for brain monitoring devices market. Today, these devices are used for understanding the conditions of patients suffering from Alzheimers disease, epilepsy, multiple sclerosis, and brain tumors amongst others. Thus, the increasing number of patients suffering from these conditions are expected to serve as a strong market driver for the global brain monitoring devices market.

The various brain monitoring devices available in the global market are intracranial pressure monitors, magnetoencephalography, electroencephalograph, cerebral oximeters, and transcranial doppler. These devices track brain function such as the velocity of blood flow in the veins and arteries in case of epilepsy, pressure surrounding the brain, electrical and neural activity, brain death, and traumatic brain injury. The market is also growing due to the rising number of post-surgical cerebrovascular accidents. These incidences have led to an augmented demand for automated brain monitoring devices in clinics and hospitals to understand the impact of anesthesia and sedatives.

Analysts note that the improvement in functionality of these devices, their user-friendliness, and affordability along with technological advancements will encourage the growth of the global market in the coming years.

Request for Analysis of COVID-19 Impact on Brain Monitoring Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1322

Global Brain Monitoring Devices Market: Geographical Outlook

On the basis of region, the global brain monitoring devices market is segmented into Asia Pacific, North America, Europe, and Rest of the World. Analysts predict that North America is expected to lead the global market as the region has a strong healthcare infrastructure. The high adoption of technology and high penetration of mobile device have given this market an edge over other regions. The brain monitoring devices market in North America is also being encouraged by the supportive regulatory framework and affordable healthcare plans. The significant rise in the geriatric population has also made its contribution to the rise of the brain monitoring devices market in North America. Research indicates that rising patient awareness about benefits of brain monitoring devices to treat disorders such as sleep apnea, Alzheimers disease, and epilepsy amongst others will also propel the regional market.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1322

Key Players Mentioned in the Report

Some of the leading players operating in the global brain monitoring devices market are Advanced Brain Monitoring, Inc., Covidien PLC, Natus Medical, Inc., and Nihon Kohden Corporation.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Pre Book Brain Monitoring Devices Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=1322&ltype=S

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

Read more information here:

https://www.transparencymarketresearch.com/brain-monitoring-devices.html

The following regional segments are covered comprehensively:

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the original:
Brain Monitoring Devices Market: High incidence of neurological disorders to drive the market - BioSpace

Neurovascular Devices/Interventional Neurology Market 2020: Latest Analysis:

The most recent Neurovascular Devices/Interventional Neurology Market Research study includes some significant activities of the current market size for the worldwide Neurovascular Devices/Interventional Neurology market. It presents a point by point analysis dependent on the exhaustive research of the market elements like market size, development situation, potential opportunities, and operation landscape and trend analysis. This report centers around the Neurovascular Devices/Interventional Neurology-business status, presents volume and worth, key market, product type, consumers, regions, and key players.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-59263?utm_source=Technoweekly/komal

The prominent players covered in this report: Stryker Corporation , Medtronic plc, Johnson & Johnson, Terumo Corporation, Penumbra, Inc., Abbott Laboratories, Merit Medical Systems, Inc., W. L. Gore & Associates, Inc., MicroPort Scientific Corporation.

The market is segmented into By Product (Embolic Coils, Stents, Neurothrombectomy Devices, Microcatheters, Balloon Occlusion Devices, Flow Diversion Devices, Clot Retrievers),By Pathology (Aneurysm, AVM).

Geographical segments are North America, Europe, Asia Pacific, Middle East & Africa, and South America.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-59263?utm_source=Technoweekly/komal

This is anticipated to drive the Global Neurovascular Devices/Interventional Neurology Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Neurovascular Devices/Interventional Neurology Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Neurovascular Devices/Interventional Neurology Market. The feasibility of the new report is also measured in this research report.

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-59263?utm_source=Technoweekly/komal

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Here is the original post:
Neurovascular Devices/Interventional Neurology Market Forecast to 2028: How it is Going to Impact on Global Industry to Grow in Near Future -...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--NeurOptics Neurological Pupil index (NPi) and automated pupillometry are now included in the updated 2020 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) as an objective measurement supporting brain injury prognosis in patients following cardiac arrest.

The AHA guidelines outline the latest global resuscitation science and treatment recommendations derived from the 2020 International Consensus on CPR and ECC and are considered the gold standard of clinical recommendations in the practice of resuscitation science. The guidelines were last updated in 2015 and reflect alignment with the International Liaison Committee on Resuscitation and associated member councils.

Automated infrared pupillometry is an objective assessment of the pupillary light reflex that is measured using NeurOptics NPi-200 Pupillometer. The NPi-200 Pupillometer provides an objective measurement of pupil size and reactivity and calculates the Neurological Pupil index (NPi). NPi values range from 0 to 4.9, with scores under 3 considered abnormal. The NeurOptics NPi-200 Pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing more accurate, reliable, and objective pupil size and reactivity measurement for this vital component of neurological examinations in patients with the potential for brain injury across a broad spectrum of conditions, including patients who have suffered cardiac arrest.

According to the new AHA guidelines, most deaths attributable to post-cardiac arrest brain injury are due to active withdrawal of life-sustaining treatment based on a predicted poor neurological outcome.1 Automated assessment of pupillary reactivity, measured by the NPi, provides a standard, reproducible measurement of pupil size and reactivity to help support the prognosis of poor neurological outcome in patients who remain comatose 72 hours after cardiac arrest.1-3

The expansion of the AHA guidelines to include automated pupillometry with the Neurological Pupil index (NPi) to monitor patients who have suffered a cardiac arrest reflects the growing adoption and validation of automated pupillometry for use in patients with brain injury, said William Worthen, President and CEO of NeurOptics. The NPi scale removes subjectivity from the neurological evaluation, providing clinicians with more accurate, objective and reliable pupil data that can be trended over time, and allows earlier detection of changes for timelier patient treatment. We are pleased to see automated pupillometry included in these new guidelines.

The 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care were published in the journal Circulation, and can be found here.

About NeurOptics

Headquartered in Laguna Hills, Calif., NeurOptics is the leader in the science of pupillometry. Driven by a passion to help clinicians improve patient outcomes, NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, and research. The NeurOptics NPi-200 Pupillometer has been included in more than 50 clinical studies, adopted in over 440 trauma and stroke centers in the United States, and is represented in more than 26 countries worldwide. For more information, visit http://www.NeurOptics.com. Follow NeurOptics on Facebook, LinkedIn and Twitter @NeurOpticsInc.

References

Go here to read the rest:
NeurOptics' Neurological Pupil index and Automated Pupillometry Included in New American Heart Association Guidelines for CPR and Emergency...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform to treat neurological disorders and diseases with an initial focus on neuropathic pain and epilepsy, today announced it has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). As part of theNIH Helping to End Addiction Long-term InitiativeSM, or NIH HEAL InitiativeSM, the funding of $670,000 over two years will be used to support CODA's plans to evaluate and advance the Company's unique receptor-ligand pairs toward the clinic for the treatment of neuropathic pain. Orion P. Keifer, Jr. M.D., Ph.D., Vice President, Discovery and Translation at CODA, will serve as the program's principal investigator.

"We are unwavering in our commitment to developing novel chemogenetic therapies for the treatment of neurological disorders and diseases like neuropathic pain for which current treatment options have significant limitations," said Michael Narachi, President and Chief Executive Officer, CODA. "We are honored to receive this grant from NINDS, as this funding will help advance our chemogenetic platform toward human clinical trials where we hope to demonstrate transformative results for patients."

CODA Biotherapeutics is developing a paradigm-shifting gene therapy approach for neuropathic pain by deploying a chemogenetic strategy for treating neuropathic pain sensations at their origin. The Company's innovative treatment aims to modulate specific neuronal circuits where pain arises via adeno-associated virus-mediated delivery of an engineered inhibitory receptor. The receptor is designed to be quiescent in the transduced cells but will specifically and dose-dependently inhibit neurons when exposed to a novel, orally bioavailable small-molecule agonist. CODA expects this treatment will produce substantially improved and durable pain relief while potentially avoiding off-target/adverse effects of currently available treatments.

The NINDS SBIR/Small Business Technology Transfer (STTR) program funds small business concerns to conduct innovative neuroscience research and/or development that has both the potential for commercialization and public health benefit.

In addition, CODA was recently selected to collaborate with NIH's National Center for Advancing Translational Science (NCATS), also as part of the NIH HEAL initiative. CODA will partner with the Stem Cell Translation Laboratory led by Ilyas Singec, M.D., Ph.D., in the NCATS Division of Preclinical Innovation (DPI) in developing induced pluripotent stem cell (iPSC)-derived human Ab sensory neurons for the identification and characterization of novel neuropathic pain therapies. The joint NCATS/CODA collaboration will leverage expertise and technologies available at Dr. Singec's lab to jointly develop protocols for generating iPSC-derived A primary sensory neurons, which CODA will then use for the identification and evaluation of inhibitory chemogenetic receptors for the treatment of neuropathic pain. G. Steven Dodson, Ph.D., Vice President of Pharmacology and Early Development at CODA will serve as lead collaborator.

"Ab neurons are a key cell type for the evaluation of our receptor-ligand combinations and their development should advance the translational understanding of how our approach may impact pain states in patients. Through this partnership, CODA will collaborate with and gain access to the scientific capabilities, expertise, state-of-the-art technologies, and resources of the NCATS DPI to develop iPSC-derived human Ab sensory neurons, which will help us progress our neuropathic pain therapies toward the clinic," added Mr. Narachi.

About Neuropathic Pain According to a study published in the Journal of Pain Research, 10 percent of the U.S. population suffers from neuropathic pain an estimated 30 million Americans. Neuropathic pain is caused by damage or disease of the sensory system, leading to chronic debilitation and loss of quality of life. Current pharmacological therapies for chronic neuropathic pain, such as opioids, anticonvulsants, and tricyclic anti-depressants, are not always effective and can have side effects, including the potential for addiction.

About the CODA Platform CODA's chemogenetic platform aims to reverse the aberrant neuronal activity underlying many neurological disorders. With chemogenetics, dysfunctional neurons are modified using optimized adeno-associated virus (AAV) vectors delivered directly to them by standard-of-care neurosurgical procedures. The AAV vectors encode ligand-gated ion channels (chemogenetic receptors) that are highly responsive to specific proprietary small molecule therapeutics but are otherwise inactive. The activity of these receptors, and thus the aberrant activity of the modified neurons, is controlled in a selective and tunable manner through administration of the small molecule to generate therapeutic benefit with minimal side effects.

About CODA BiotherapeuticsCODA Biotherapeutics, Inc., is a preclinical-stage biopharmaceutical company developing an innovative gene therapy platform to treat neurological disorders and diseases. The Company is creating the ability to control neurons with its revolutionary chemogenetics-based technology. CODA is located in South San Francisco, CA. For more information, please visit http://www.codabiotherapeutics.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coda-biotherapeutics-receives-grant-from-the-national-institute-of-neurological-disorders-and-stroke-ninds-of-the-national-institutes-of-health-nih-to-help-advance-its-next-generation-gene-therapy-mediated-chemogenetic-platfor-301168028.html

SOURCE CODA Biotherapeutics, Inc.

See the rest here:
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health...

MarketsandResearch.biz has published a new report titled Global Interventional Neurology Device Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that aims to define the market size of different segments in previous years and to forecast the values to the next five years. The report entails a comprehensive database on market estimation based on historical data analysis. The report emphasizes knowledge-based information on both qualify qualitative and quantitative aspects of the industry. It covers the new players entering the global Interventional Neurology Device market. It focuses on primary and secondary drivers, market share, leading segments, and regional analysis. Then the report demonstrates detailed information about the crucial aspects such as drivers and restraining factors which will show the future growth of the market.

The most recent improvements and new industrial explanations are revealed in the report. Report analysts analyze the key elements such as demand, growth rate, cost, capacity utilization, import, margin, and production of the global market players. The report further focuses on global major leading industry players of the global Interventional Neurology Device market providing information such as company profiles, product picture, and specification, production, price, cost, revenue, and contact information. Details of different sections and sub-sections of the global market on the basis of topographical regions have been given. In terms of a global perspective, this report represents the overall market size by analyzing historical data and future prospects.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/74333

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Primitive vendors included in the market are: Medtronic, Medikit Co., Ltd., Penumbra, Inc., Johnson and Johnson, Microport Scientific Corporation, Terumo Corporation, W.L. Gore & Associates, Merit Medical Systems, Inc, Stryker

Market Scenario:

The report also highlights on its applications, types, deployments, components, developments of this market. It scrutinizes a number of potential growth factors, risks, restraints, challenges, market developments, opportunities. The development of the industry is assessed with information on the current status of the global Interventional Neurology Device industry in various regions. The report also covers the recent agreements including merger & acquisition, partnership or joint venture, and the latest developments of the manufacturers.

The product types covered in the report include: Embolization & coiling, Neurothrombectomy Devices, etc.

The application types covered in the report include: Treatment of Cerebral Aneurysms, Treatment of Cerebral Vasospasm, Vertebroplasty, etc.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/74333/global-interventional-neurology-device-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Regional Segmentation:

The global version of this report with a geographical classification such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa). The authors of the report have studied the regions having growth potential to help companies plan their future investments. Key regions are assessed, with sales, revenue, market share, and growth rate of Interventional Neurology Device in these regions, from 2020 to 2025. This chapter also studies the regulatory reforms and norms that are expected to impact the global market.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

View post:
Global Interventional Neurology Device Market 2020 | Demand and Scope with Outlook, Business Strategies, Challenges and Forecasts to 2025 -...

PARIS, Nov. 2, 2020 /PRNewswire/ -- Corlieve Therapeutics today announced the closing of its seed financing led by Kurma Partners and IDinvest Partners, together with Pureos Bioventures. Corlieve is focused on developing novel therapeutics for severe neurological disorders.

Corlieve's lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. The program is based on pioneering science from INSERM, CNRS, Aix Marseille University and the University of Bordeaux, and is being developed in collaboration with REGENXBIO Inc. (Maryland, US), a leading gene therapy company. In addition, Corlieve has licensed REGENXBIO's NAV AAV9 technology for the TLE program. Corlieve is led by Chief Executive Officer Richard Porter, Ph.D., who brings to the Company over 25 years of neuroscience leadership experience in the pharmaceutical and biotech industries, including most recently as Chief Operating Officer of Therachon Holding AG until its acquisition by Pfizer in July 2019.

"I am excited to build Corlieve on a strong scientific foundation and with valuable support from our partners and investors," said Dr. Porter. "Our novel approach allows us to bring potentially game-changing treatments to patients with neurological diseases."

Corlieve's board will consist of Vanessa Malier, Managing Partner at Kurma, Anja Harmeier, Partner at Pureos Bioventures and Olivier Danos, Ph.D., Chief Scientific Officer of REGENXBIO.

"The formation of Corlieve with REGENXBIO is another validation of our approach to build companies on the basis of leading French science combined with a strong technology partner. We at Kurma are thrilled to support this emerging science to tackle TLE," said Ms. Malier.

"Our mission at REGENXBIO is to develop and enable the use of our proprietary NAV Technology Platform to advance new gene therapies for diseases with significant unmet needs," said Dr. Danos. "We are pleased to collaborate with Corlieve in this application of our NAV AAV9 technology to potentially treat patients suffering from TLE, for which better treatment modalities are needed."

Story continues

About Corlieve TherapeuticsCorlieve Therapeutics is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders. The lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with TLE using a gene therapy approach.

About KurmaKurma Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I through III and Kurma Diagnostics, as well as via strategic partnerships with prestigious European research and medical institutions.

About IDinvestIdinvest Partners is a leading European mid-market private equity firm. With 8bn under management, the firm has developed several areas of expertise including innovative start-up venture capital transactions; mid-market private debt, i.e. single-tranche, senior and subordinated debt; primary and secondary investment and private equity advisory services.

About Pureos BioventuresPureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug modalities. The fund's portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases and neuroscience. Pureos has built a team with deep investment, operating and clinical expertise, that strives to impact patients' lives by advancing innovative treatments for devastating diseases.

About REGENXBIOREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contact: Amy Conrad, 858-366-3243, amy@juniper-point.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/corlieve-therapeutics-sas-closes-seed-financing-to-develop-therapies-for-severe-neurological-conditions-301164506.html

SOURCE Corlieve Therapeutics

The rest is here:
Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions - Yahoo Finance

Its high in fat, moderate in protein, and low in carbohydratesthe ketogenic diet is known for helping patients lose weight. But sleep medicine Dr. Jose Colon says, if done correctly, the diet can improve more than just your weight. Being on a ketogenic diet or being in a state of ketosis, has been shown to help with epilepsy and many other disorders as well, Dr. Jose Colon, a sleep medicine physician with Lee Health.

Doctors use the ketogenic diet to help treat patients with seizures. The ketogenic diet is very effective in epilepsy but its also been shown to be helpful in many other medical disorders, from weight loss to diabetes, type two diabetes, insulin resistance, it can help with PCOS, and it helps brain function from pediatric to geriatric, from autism to Alzheimers, he said.

The keto diet can also benefit patients who suffer from sleep disorders. Ive had several patients also have successful treatment of narcolepsy as well with the ketogenic diet. One of the things with narcolepsy is that your brain is in a sleepy state and high carbohydrate states turn off your alerting neurons so it can help with that disorder as well, said Dr. Colon.

Doctors can help patients successfully adapt and maintain a ketogenic diet. A lifestyle change that can benefit their overall health.

View More Health Matters video segments at LeeHealth.org/Healthmatters/

Lee Health in Fort Myers, FL is the largest network of health care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For more than 100 years, weve been providing our community with personalized preventative health services and primary care to highly specialized care services and robotic assisted surgeries. Lee Health Caring People. Inspiring Care.

Visit LeeHealth.org

Read more from the original source:
Health Matters: Neurology and the Keto Diet - NBC2 News

A neurologist at the centre of Northern Ireland's biggest ever patient recall will contest a decision to appeal his voluntary removal from the medical register, the High Court heard today.

ounsel for Dr Michael Watt confirmed his intention to resist the surprise intervention by an oversight body.

Lawyers representing former patients welcomed the step taken by the Professional Standards Authority (PSA), but stressed they must not be shut out from the legal process.

In October the Medical Practitioners Tribunal Service (MPTS) granted Dr Watt's application for voluntary erasure from the register.

The regulator's controversial decision means the former Belfast Trust consultant will not face a public hearing into concerns about his work.

His inability to engage with a fitness to practice assessment and the potential risk of suicide were cited among the reasons.

Some of those Dr Watt treated are seeking a judicial review of the lawfulness of the decision.

Danielle O'Neill, 39, claims there was no jurisdiction for the move which breaches her human rights.

Belfast man Michael McHugh, 51, also alleges it was an unjust step, denying public scrutiny of the neurologist's work.

But it has now emerged that the PSA, which oversees regulators, has lodged a High Court appeal against the MPTS decision to allow voluntary removal.

A judge questioned whether the judicial review challenges should be put on hold pending the outcome of the separate legal action.

He was told that the neurologist intends to oppose the PSA's challenge.

David Dunlop QC confirmed: "It will come as no surprise that Dr Watt will be contesting the appeal, on the grounds that it seeks to challenge the basis on which the voluntary erasure application was approved."

During the hearing counsel representing Ms O'Neill, Dessie Hutton QC, reiterated claims that the MPTS decision was a nullity.

"If that argument is correct, there was never any basis for the decision, and there is no basis for the appeal," he submitted.

Adjourning proceedings, Mr Justice Colton stressed all of the cases should be reviewed again as soon as possible.

Outside court Ms O'Neill insisted that her legal action represents an opportunity for patients' to be heard.

She added: "I find it galling that Dr Watt, who should have a back seat in these proceedings, after all we have suffered, is now seeking to dictate how our cases will be heard."

Her solicitor claimed the voluntary removal decision had closed off the only remaining public hearing into alleged clinical failings which have caused "harm and immeasurable distress".

Claire McKeegan of Phoenix Law said: "Our clients (in the) Neurology Recall Support Group, who have been injured and traumatised, welcome the intervention of the Professional Standards Authority but wish to have a voice and participate in the court process." end

Link:
Neurologist at centre of NI's biggest ever patient recall Dr Michael Watt will contest decision to appeal his voluntary removal from medical register...

image:Katerina Akassoglou, senior investigator at Gladstone Institutes, is named a fellow of the National Academy of Inventors for her long track record of discovery and innovation. view more

Credit: Gladstone Institutes

Katerina Akassoglou, PhD, senior investigator at Gladstone Institutes, has been named a fellow of the National Academy of Inventors (NAI). Election to NAI is the highest professional distinction given solely to academic inventors.

This prestigious recognition is a testament to Akassoglous long track record of discovery and innovation. She has made seminal discoveries on the relationship between the brain, immune, and vascular systems. Her research has illuminated the toxic role of blood proteins in neurological diseases and has led to the development of therapeutics to treat these diseases.

Akassoglou holds 10 issued US patents and several pending patent applications, many of which have been licensed by biomedical companies. She co-founded the startup Therini Bio with technology spun out from her laboratory for the clinical development of these discoveries.

Katerina exemplifies Gladstones commitment to innovation, invention, and translational research that has the potential to benefit patients, says Gladstone President Deepak Srivastava, MD. We are incredibly proud that she has been recognized with this well-deserved honor.

Akassoglou was named an NAI Fellow for demonstrating a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and welfare of society.

I am truly honored to be elected to the National Academy of Inventors in recognition of our discoveries and grateful for the support of academic innovation, says Akassoglou, who is also director of the Center for Neurovascular Brain Immunology at Gladstone and UCSF, and professor of neurology at UC San Francisco. Election to the NAI further encourages us to pursue challenging problems in biology and medicine to develop urgently needed treatments for devastating human diseases.

Akassoglous research team discovered that blood proteins are toxic when they enter the brain in neurological diseases because they induce inflammation and inhibit repair. They showed that in neurodegenerative diseasesincluding multiple sclerosis and Alzheimers diseasethe blood-clotting protein fibrin leaks through the blood-brain barrier into the brain. There, it hijacks receptors on nervous system cells and can activate microglia (the brains resident immune cells), triggering inflammation and, eventually, nerve damage.

With this knowledge, Akassoglou invented an antibody to neutralize the toxic effects of blood in disease. This first-in-class immunotherapy targets fibrin and prevents it from activating immune cells, but doesnt impair its beneficial blood clotting function. In mouse models of Alzheimers disease, the antibody prevents neurodegeneration, even when administered after mice have already developed accumulations of amyloid proteins in the brain, a hallmark of disease. Similarly, in a mouse model of multiple sclerosis, the fibrin antibody prevented paralysis, nerve damage, and inflammation. Her lab also developed a fibrin therapeutics platform and, together with collaborators, discovered small molecule drugs to block the deleterious effects of fibrin on nervous system cells with potent protection from neurodegeneration.

Akassoglou is among 164distinguished academic inventors from 116universities and research institutes elected to the NAI this year. She becomes the second Gladstone researcher to be an NAI Fellow, with Senior Investigator Jennifer Doudna, PhD. An induction ceremony for newly elected NAI Fellows will be held at the organizations 11th annual meeting in June2022 in Phoenix, Arizona.

The program currently has 1,403Fellows worldwide representing more than 250 universities and research institutes. Collectively, fellows hold more than 42,700issued US patents, which the NAI estimates have generated more than $3trillion in revenue and created more than 1million jobs.

###

About the National Academy of Inventors

The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office (USPTO), enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society. The NAI has a close partnership with the USPTO and is one of three honorific organizations, along with the National Medals and National Inventors Hall of Fame, working closely with the USPTO on many discovery and innovation support initiatives. The NAI publishes the multidisciplinary journal,Technology and Innovation.

About Gladstone Institutes

To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See original here:
Katerina Akassoglou elected to National Academy of Inventors - EurekAlert

This versatile composition of research derivatives pertaining to diverse concurrent developments in the global Neurology Software market is poised to induce forward-looking perspectives favoring unfaltering growth stance.

A newly compiled research report presentation on global Neurology Software market is aimed to unfurl veritable details about growth prognosis that are effectively harnessed by prominent market drivers and growth influencers.

The report also sheds light on various growth deterrents and retardants to offer a decisive understanding on barrier analysis to optimally identify growth retardants that stun growth in global Neurology Software market. In further report highlights, readers are equipped with thorough understanding on barrier identification and threat evaluation

Vendor Profiling: Global Market_Keywor Market, 2019-25:

DROT Analysis Driver Assessment: This section of the report also clearly identifies the major growth enablement triggers and drivers that push the growth trajectory.

Understanding Growth Retardants: This report further entails crucial details on notable growth hindering aspects that significantly arrest smooth growth ride. Besides identifying major growth retardants, the report proceeds further with assessing catastrophic developments.

Understanding Opportunities: The report proceeds further with unraveling details on dominant as well as latent opportunities that ensure growth spurt through the growth span. This section of the report also includes veritable details on various M&A developments, commercial collaborations as well as segment wise advances that collectively direct optimistic growth.

We Have Recent Updates of Neurology Software Market in Sample [emailprotected] https://www.orbismarketreports.com/sample-request/121767?utm_source=PujaM

Favoring utmost reader comprehension about the Neurology Software market to ensure lucrative business returns, this mindful report is designed to include a dedicated chapter on pre and post COVID analysis to encourage steady recovery from the pandemic, affecting production and consumption facets critically.

Analysis by Type: This section of the report includes factual details pertaining to the most lucrative segment harnessing revenue maximization.

Analysis by Application: Further in the subsequent sections of the report, research analysts have rendered precise judgement regarding the various applications that the Neurology Software market mediates for superlative end-user benefits.

Browse Full Report with Facts and Figures of Neurology Software Market Report at @ https://www.orbismarketreports.com/global-neurology-software-market-analysis-by-growth-and-forecast-2025?utm_source=PujaM

Understanding Competition Spectrum: Global Neurology Software Market

In addition to the above, this dedicated research report representing the current and historical developments in the global Neurology Software market have been prioritized exponentially in report contents to ensure seamless growth oriented business discretion amongst frontline players

The report is as well designed to suit investment priorities of emerging market participants keen at sustaining indispensable market position amidst glaring odds and market challenges, inclusive of escalating competition.

This section of the report clearly demarcates the key market participants and contributors along with key manufacturers putting in dedicated efforts towards pandemic management.

Despite the temporary dip in growth prognosis owing the pandemic crisis, market participants in global Neurology Software market are scouting for accurate business strategies to emerge and offset critical growth deterrents in global Neurology Software market.

Brief on their company positioning, product and service status as well as likelihood of future investments as well as thorough objective analysis of the companies have been showcased in the report.

This highly classified information has been obtained post tremendous primary research practices undertaken by our inhouse research teams.

North America (U.S., Canada, Mexico) Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS) Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific) Latin America (Brazil, Rest of L.A.) Middle East and Africa (Turkey, GCC, Rest of Middle East)

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected] https://www.orbismarketreports.com/enquiry-before-buying/121767?utm_source=PujaM

The report offers a clear and accessible estimation of the global Neurology Software market that are presented as value based and volume based estimations. The report is mindfully structured to present all market relevant information which are designed and presented in the form of graphs, charts and tables to allow market players quickly decipher the peculiarities to invoke mindful business decisions

Global Neurology Software Market: Understanding Scope In-depth research and thorough evaluation of the various contributing factors reveal that the global Neurology Software market is estimated to perform decently in forthcoming years, reaching a total valuation of xx million USD in 2019, and is further poised to register xx million USD in 2025, growing at a healthy CAGR of xx%. This elaborate research report also houses extensive information of various market specific segments, elaborating further on segment categorization comprising type, application as well as end-user sections which successively influence lucrative business discretion.

The report also entails a dedicated section and chapter to offer market relevant highlights denoting consumption and production activities. The report also entails sectional representation of thorough barrier evaluation and threat probabilities. The report clearly highlights the details of vendor activities and promotional investments, crucial to ensure high return on investments.

About Us : We are a team of highly professional researchers dedicated to unravel ongoing market developments. We are recognized as best in industry one stop store, offering intensively researched market-oriented information with superlative standards of impartiality and authenticity in order to rightfully influence favorable business decisions across a range of verticals.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

More:
Global Neurology Software Market Expected to Reach highest CAGR: Epic, Athenahealth, Nextgen, healthfusion, Allscripts etc. - The Think Curiouser

Article In Brief

Investigators reported anti-SARS-CoV-2 autoantibodies in the cerebrospinal fluid of three teens who came to the emergency department with neuropsychiatric symptoms. The scientists believe that emergency department doctors should be open to the possibility that young people presenting for the first time with unexplained neuropsychiatric problems could have an autoantibody response to the COVID-19 infection, and should be evaluated accordingly.

Scientists have identified anti-SARS-CoV-2 antibodies and anti-neuronal auto-antibodies in the cerebrospinal fluid (CSF) of two of three teenagers who presented to an emergency department with subacute neuropsychiatric problems, including paranoid delusions, suicidal ideation, anxiety, obsessive behavior, and cognitive slowing.

While many teenagers present to the emergency department with neuropsychiatric symptoms, these three teens were the only ones who presented to the University of California, San Francisco (UCSF) with these symptoms in the setting of a recent COVID-19 infection and for whom a neurology consult was called. Two tested positive with direct detection tests, and one was seropositive (antibody testing) with a recent exposure.

All three also had abnormal CSF with restricted oligoclonal bands, elevated protein, and/or an elevated immunoglobulin G (IgG) index. None of them met the criteria for multisystem inflammatory syndrome in children, which has been associated with some cases of COVID-19 in young patients.

The findings, published online on October 25 in JAMA Neurology, suggest that the virus could be associated with central nervous system inflammation and leave some pediatric COVID-19 patients with new onset neuropsychiatric symptoms that do not respond to traditional psychiatric medications.

One of the teenagers seemed to improve after immunotherapy, another had a modest response, while the third teens' symptoms improved after treatment with lorazepam and olanzapine without immunotherapy.

The scientists believe that emergency department doctors should be open to the possibility that young people presenting for the first time with unexplained neuropsychiatric problems could have an auto-antibody response to the COVID-19 infection, and should be evaluated accordingly.

We don't know if this could be a more general phenomenon, said the senior study author Michael R. Wilson, MD, FAAN, associate professor and Debbie and Andy Rachleff Distinguished Chair in neurology at the UCSF Weill Institute for Neurosciences. Scientists at UCSF are now analyzing CSF from more young people.

Together with Samuel J. Pleasure, MD, PhD, the Glenn W. Johnson, Jr. Memorial Endowed Chair in Neurology at UCSF, Dr. Wilson, and first co-author Christopher Bartley, MD, PhD, have been using multiple technologiesgenomics, immune system sequencing techniques, and phage displayto characterize the immune system's response to pathogens and to screen for antibodies in the CSF of COVID-19 patients with neurologic symptoms.

For this latest study, the scientists conducted a detailed analysis of CSF and blood from three teenagers presenting to UCSF Benioff Children's Hospital with neurological or psychiatric symptoms during a five-month period in 2020.

In the first case, UCSF pediatric resident Claire Johns, MD, had evaluated a teenager who presented with acute delusions and psychosis, and called on the neurology service to help assess the patient. The teenager had erratic and paranoid-like behavior, insomnia and social withdrawal. The teen had a history of marijuana use and unspecified anxiety and depression, was initially treated with psychiatric medications, but was discharged after 11 days. The teen was readmitted a day later with persistent delusions.

The teenager had tested positive for COVID-19 during the first hospitalization, although the teen had no respiratory symptoms. On readmission, a lumbar puncture showed elevated protein and elevated IgG index. An MRI of the brain showed non-specific T2/FLAIR white matter hyperintensities in the frontal lobes. The pediatric specialists ordered intravenous immunoglobulin (IVIg) and the teen quickly improved enough to be discharged from the hospital. The teen's blood and CSF were later sent for further analysis to Dr. Wilson and his colleagues who identified abnormal antibody production in the teen's CSF.

The second teen had a history of anxiety and motor tics and a foggy brain,: according to the description in the paper. The teen's father had just been diagnosed with COVID-19, and a week later the teen developed fever and respiratory symptoms and improved without treatment. Over the next six weeks, the teen experienced a host of neuropsychiatric symptoms, including word-finding difficulty and problems concentrating, insomnia, mood swings, and it morphed into aggression and suicidal ideation. The teen was treated without success with psychiatric medications, and admitted to the hospital ten weeks after the neuropsychiatric symptoms began.

Back in the hospital, the patient tested positive for SARS-CoV2 antibodies. The teen's slowed thinking and memory problems improved after IV methylprednisolone, and was discharged on lithium and risperidone. Six days later, still in the throes of aggression and suicidal ideation, the teen was readmitted. Another lumbar puncture showed elevated CSF protein and IVIg was administered for three days. The patient was discharged with psychiatric medicines but six months later there was still lingering forgetfulness and attention problems. A third lumbar puncture at six months still showed elevated protein.

The third teenager was taken to the emergency department after four days of extremely erratic and odd repetitive behaviors, insomnia, and anorexia. There was no previous history of psychiatric symptoms. In the ED, a SARS-CoV-2 test came back positive. The teen had an elevated white blood cell count, creatine kinase, and C-reactive protein as well as ideomotor apraxia, a lack of motivation, disorganized behavior, and agitation. Psychiatric medications were administered for a few days and then stopped. The patient's symptoms improved during the weeklong hospitalization, and the teen was discharged without any psychiatric medications.

One important difference is that the teen who improved was treated soon after their symptoms started whereas the second patient's treatment was delayed by over two months, said Dr. Johns. The third young person had mania and insomnia and tested positive for SARS-CoV2 but did not have evidence of auto-antibodies in the CSF.

You get to one underlying question: SARS-CoV-2 is infecting millions and millions of people, and a great majority don't get critically ill. The ones who do tend to be older and/or have co-morbidities. What we don't know is if there are underlying issues that put certain people at risk for neuropsychiatric problems or long COVID, said Dr. Pleasure.

Merely identifying these autoantibodies and some of their antigens does not causally link them to these young peoples' symptoms, added Dr. Bartley. In some patients, the specific regions of the SARS-CoV-2 proteome targeted by the serum antibodies differed from the antigens in the CSF, suggesting that a compartmentalized immune response might be occurring in the CNS.

But we won't build more confidence about a potential link until we've been able to assess additional patients to determine whether these autoantibodies consistently track with particular clinical phenotypes. Ultimately, these autoantibodies may be reflective of a broader immune dysregulation that is related to their symptoms, but it's too early to tell. These teenagers were treated as psychiatric patients and COVID was found incidentally. We should definitely have this on our radar. Some of these patients may have subtle evidence of neuroinflammation and warrant a different treatment approach.

The scientists published previous studies in 2020 that led up to this latest work. In a paper Cell Reports Medicine done in close collaboration with Shelli Farhadian, MD, PhD, and Serena Spudich, MD, at Yale University, they identified early evidence for CSF anti-neural autoantibodies using mouse brain tissue to look for immunofluorescence. They identified some of the antibody targets using a combination of immunoprecipitation-mass spectrometry with rodent brain lysates and phage display. Then, they validated their finding in tissue culture cells engineered to express these antigens. Ultimately, five of the seven adults had evidence for CSF autoantibodies.

The immune response was so jazzed up, said Dr. Pleasure. It is not at all clear yet whether these antibodies, some of which appear to be cross-reactive between SARS-CoV-2 and neural antigens, are responsible for any of the neuropsychiatric symptoms.

The UCSF team now has samples from more than 50 COVID-19 patients who have unexplained neuropsychiatric symptoms. UCSF scientists are also studying patients with long-haul COVID, and Dr. Bartley said that they want to run the same types of experiments to see if they can identify auto-antibodies that may correlate with their enduring symptoms.

This is an important study that links infectious SARS-CoV-2 with neurological and neuropsychiatric complications in young people, said Carlos A. Pardo, MD, professor of neurology and pathology at Johns Hopkins Medicine and division of neuroimmunology and neuroinfectious disorders. The finding of auto-antibodies in spinal fluid is fascinating. It implicates the immunological responses in the brain, or unmasks the immunological responses against the brain.

We need to better characterize the mechanism of how the antibody triggers acute and long-term neuropsychiatric problems, added Dr. Pardo, who also studies CSF in patients with difficult neurological complications, including COVID-19. His laboratory recently published a study in The Journal of Neurological Sciences showing that almost 77 percent of patients with COVID-19 neurological complications had anti-SARS-CoV2 antibodies in their CSF.

The new study in JAMA Neurology opens the door to see how COVID triggers neurological and neuropsychiatric symptoms, he added. We are still a bit far away from recommending immune-based treatments.

There is currently great interest among neurologists regarding the potential for COVID infections to stir up an autoinflammatory process and induce autoimmunity resulting in a targeted immune attack against proteins in the brain, said Sean J. Pittock, MD, director of Mayo Clinic's center for multiple sclerosis and autoimmune neurology and of Mayo's neuroimmunology laboratory. Patients with COVID infections may develop encephalopathies but the immunopathological mechanisms underlying these remain unclear.

In this study, the UCSF scientists used their human phage display immunoprecipitation sequencing (testing for antibodies targeting the entire human proteome) and identified a multitude of autoantigens. The heterogenous autoantigen signature identified between patients indicates complexity and makes conclusions difficult, Dr. Pittock said. The identification of two potential novel targets in Case 1 is of interest but again the clinical implications remain unclear.

Many patients without autoimmune disease harbor autoantibodies (organ and non-organ specific).The two protein targets reported in this paper are intracellular proteins, thus it is unlikely that antibodies targeting such proteins are pathogenic, he added. Antibodies targeting intracellular proteins can indicate a pathogenic T cell response, however, if this were the case one would expect a more persistent and less responsive disorder than transient, as in these patients.

Overall, these findings are interesting and raise lots of questions which should stimulate more research in this area, Dr. Pittock said. Future studies investigating larger numbers of patients with COVID-associated encephalopathies will hopefully define the antibody, chemokine and cytokine signatures of this and other viral encephalopathies. This will further our understanding of these conditions and potentially identify therapeutic targets allowing repurposing of biologics for therapy.

He also said that although not applicable in this study, we must be careful in drawing too many conclusions: young patients develop primary psychiatric illness frequently, and when this diagnosis is combined with high levels of concomitant infection, there may or may not be a causal relationship.

The findings are pointing us in an intriguing direction, added Sarosh Irani, MD, associate professor at University of Oxford and head of the Oxford Autoimmune Neurology Group. These young people had atypical forms of encephalitis. The patients were identified retrospectively and it's not known if their neuropsychiatric symptoms would have occurred anyway or were due to COVID. Nevertheless, this is a very interesting preliminary finding and now needs validation in a larger consecutive cohort, ideally the pre-and post-COVID era.

Read more here:
COVID-19 and Neuropsychiatric Symptoms in Teenagers : Neurology Today - LWW Journals

This article was originally published here

Curr Opin Immunol. 2021 Dec 1;74:118-124. doi: 10.1016/j.coi.2021.11.006. Online ahead of print.

ABSTRACT

In the central nervous system (CNS) parenchymal macrophages are called microglial cells and have a distinct developmental origin and can self-renew. However, during pathological conditions, when the blood-brain-barrier becomes leaky, including after injury, in multiple sclerosis or with glioblastoma, monocyte-derived macrophages (MDM) infiltrate the CNS and cohabit with microglia. In neurodegenerative diseases such as Alzheimers disease or ALS, MDM mostly do not enter the CNS, and instead microglia take several identities. In the specific case of ALS, the affected motor neurons are even surrounded locally by microglia, while along the peripheral nerves, by MDM-derived macrophages. The specific functions and interactions of these different myeloid cells are only starting to be recognized, but hold high promise for more targeted therapies.

PMID:34864338 | DOI:10.1016/j.coi.2021.11.006

Read the original post:
Local and remote interactions between macrophages and microglia in neurological conditions - DocWire News